Literature DB >> 16133893

Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients.

Vivian W Y Lee1, Joyce H S You, Kenneth K C Lee, T S Chau, Mary M Y Waye, Gregory Cheng.   

Abstract

BACKGROUND: Multiple factors can affect the anticoagulation effect of warfarin. The objective of this study was to determine the relationship between different clinical factors and outcomes of warfarin therapy in Hong Kong Chinese patients.
METHODS: The study was conducted at the anticoagulation clinic of the Prince of Wales Hospital from 1 April to 31 December 2003. Clinical data collected included demographics, indications of warfarin, dietary vitamin K consumption, and drug-drug interactions. Blood samples were obtained for the genetic polymorphism analysis of CYP 2 C 9. Linear and multiple regression analysis were used for statistical analysis to determine the correlation between variables and the importance of various factors as the determinants of warfarin dosage requirement.
RESULTS: A total of 63 patients were recruited. The mean warfarin dosage was 3.30+/-2.23 mg/day. The warfarin dosage ranged from 0.75 to 12 mg/day. The mean age was 59+/-14 years old. Age, dietary vitamin K consumption, chronic heart failure, atrial fibrillation, hypertension, smoking and drinking status were found to be factors statistically significant affecting warfarin dosage. We detected no single nucleotide polymorphism in CYP 2 C 9 exon 4.
CONCLUSION: Age, dietary vitamin K consumption, warfarin indication for atrial fibrillation, co-morbid with CHF, smoking and drinking status were found to be the factors that affected the warfarin requirement in Hong Kong Chinese patients. However, the genetic polymorphism in exon 4 of CYP 2 C 9 may not be associated with the warfarin sensitivity in this patient population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133893     DOI: 10.1007/s11239-005-3121-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  23 in total

1.  No exon 4 polymorphism of cytochrome P450 CYP2C9 in Taiwanese.

Authors:  Jan-Gowth Chang
Journal:  Blood       Date:  2003-06-15       Impact factor: 22.113

2.  Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol.

Authors:  G W Roberts; T Druskeit; L E Jorgensen; L M Wing; A S Gallus; C Miller; D Cosh; V S Eaton
Journal:  Aust N Z J Med       Date:  1999-10

3.  Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K.

Authors:  R R Couris; G R Tataronis; S L Booth; G E Dallal; J B Blumberg; J T Dwyer
Journal:  J Am Coll Nutr       Date:  2000 Nov-Dec       Impact factor: 3.169

4.  The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.

Authors:  F Kamali; C Edwards; T J Butler; H A Wynne
Journal:  Thromb Haemost       Date:  2000-07       Impact factor: 5.249

5.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

Review 6.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

7.  Investigations of the effects of ethanol on warfarin binding to human serum albumin.

Authors:  C E Ha; C E Petersen; D S Park; K Harohalli; N V Bhagavan
Journal:  J Biomed Sci       Date:  2000 Mar-Apr       Impact factor: 8.410

8.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Authors:  Farhad Kamali; Tayyaba Irfan Khan; Barry P King; Richard Frearson; Patrick Kesteven; Peter Wood; Ann K Daly; Hilary Wynne
Journal:  Clin Pharmacol Ther       Date:  2004-03       Impact factor: 6.875

9.  Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin.

Authors:  T Khan; H Wynne; P Wood; A Torrance; C Hankey; P Avery; P Kesteven; F Kamali
Journal:  Br J Haematol       Date:  2004-02       Impact factor: 6.998

Review 10.  Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.

Authors:  L G Miller
Journal:  Arch Intern Med       Date:  1998-11-09
View more
  9 in total

1.  Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.

Authors:  Sameer Ather; Aditi Shendre; T Mark Beasley; Todd Brown; Charles E Hill; Sumanth D Prabhu; Nita A Limdi
Journal:  Am J Cardiol       Date:  2016-05-05       Impact factor: 2.778

2.  Evaluation of the effects of ontogenetic or maturation functions and chronic heart failure on the model analysis for the dose-response relationship of warfarin in Japanese children.

Authors:  Rika Tamura; Nao Watanabe; Saki Nakamura; Naoki Yoshimura; Sayaka Ozawa; Keiichi Hirono; Fukiko Ichida; Masato Taguchi
Journal:  Eur J Clin Pharmacol       Date:  2019-03-08       Impact factor: 2.953

3.  Impact of a pharmacotherapeutic programme on control and safety of long-term anticoagulation treatment: a controlled follow-up study in Spain.

Authors:  Carmen Duran-Parrondo; Juan M Vazquez-Lago; Ana M Campos-Lopez; Adolfo Figueiras
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

4.  Evaluation of an Initiation Regimen of Warfarin for International Normalized Ratio Target 2.0 to 3.0.

Authors:  Sahimi Mohamed; Chan Mei Fong; Yew Jie Ming; Ahlam Naila Kori; Sopian Abdul Wahab; Zarina Mohd Ali
Journal:  J Pharm Technol       Date:  2021-08-05

5.  The Prediction Model of Warfarin Individual Maintenance Dose for Patients Undergoing Heart Valve Replacement, Based on the Back Propagation Neural Network.

Authors:  Qian Li; Jing Wang; Huan Tao; Qin Zhou; Jie Chen; Bo Fu; WenZhe Qin; Dong Li; JiangLong Hou; Jin Chen; Wei-Hong Zhang
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

6.  Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy.

Authors:  Behzad Poopak; Saghar Rabieipoor; Nazila Safari; Emadedin Naraghi; Fatemeh Sheikhsofla; Gelareh Khosravipoor
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-10-01

7.  Identification of clinical factors predicting warfarin sensitivity after cardiac surgery.

Authors:  Karen Tyson; Nevil Hutchinson; Sian Williams; Greg Scutt
Journal:  Ther Adv Drug Saf       Date:  2018-06-05

Review 8.  Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.

Authors:  Andrea L Jorgensen; Richard J FitzGerald; James Oyee; Munir Pirmohamed; Paula R Williamson
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

9.  Impact of body mass index on 90-day warfarin requirements: a retrospective chart review.

Authors:  Bolanle M Soyombo; Ashley Taylor; Christopher Gillard; Candice Wilson; Janel Bailey Wheeler
Journal:  Ther Adv Cardiovasc Dis       Date:  2021 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.